Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans

60Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Biotherapeutics are expanding the arsenal of therapeutics available for treating and preventing disease. Although initially thought to have limited side effects due to the specificity of their binding, these drugs have now been shown to have potential for adverse drug reactions including effects on peripheral blood cell counts or function. Hematotoxicity caused by a biotherapeutic can be directly related to the activity of the biotherapeutic or can be indirect and due to autoimmunity, biological cascades, antidrug antibodies, or other immune system responses. Biotherapeutics can cause hematotoxicity primarily as a result of cellular activation, cytotoxicity, drug-dependent and independent immune responses, and sequelae from initiating cytokine and complement cascades. The underlying pathogenesis of biotherapeutic-induced hematotoxicity often is poorly understood. Nonclinical studies have generally predicted clinical hematotoxicity for recombinant cytokines and growth factors. However, most hematologic liabilities of biotherapeutics are not based on drug class but are species specific, immune-mediated, and of low incidence. Despite the potential for unexpected hematologic toxicity, the risk-benefit profile of most biotherapeutics is favorable; hematologic effects are readily monitorable and managed by dose modification, drug withdrawal, and/or therapeutic intervention. This article reviews examples of biotherapeutics that have unexpected hematotoxicity in nonclinical or clinical studies. © 2013 by The Author(s).

References Powered by Scopus

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease

1980Citations
N/AReaders
Get full text

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγrIIIa gene

1733Citations
N/AReaders
Get full text

VEGF inhibition and renal thrombotic microangiopathy

1306Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Immunogenicity of therapeutic proteins: Influence of aggregation

472Citations
N/AReaders
Get full text

Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: A randomized phase II trial

196Citations
N/AReaders
Get full text

Engineering an IgG scaffold lacking effector function with optimized developability

63Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Everds, N. E., & Tarrant, J. M. (2013). Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicologic Pathology, 41(2), 280–302. https://doi.org/10.1177/0192623312467400

Readers' Seniority

Tooltip

Researcher 18

49%

PhD / Post grad / Masters / Doc 15

41%

Professor / Associate Prof. 3

8%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

35%

Biochemistry, Genetics and Molecular Bi... 11

30%

Agricultural and Biological Sciences 7

19%

Pharmacology, Toxicology and Pharmaceut... 6

16%

Save time finding and organizing research with Mendeley

Sign up for free